Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
rocatinlimab
Class :
Anti-OX40 Human Monoclonal Antibody
Brand Name :
N/A
Synonyms :
rocatinlimab
Class :
Anti-OX40 Human Monoclonal Antibody
Dosage Forms & Strengths
Pending for FDA approval for moderate-to-severe atopic dermatitis rocatinlimab has shown promising results in a Phase 2b clinical trial in terms of efficacy and safety for this specific indication.
Actions and Spectrum:
rocatinlimab (previously known as BMS-986242) was a novel investigational monoclonal antibody. It was being studied for its potential therapeutic effects in several diseases and conditions related to the immune system.
Actions:
rocatinlimab is a monoclonal antibody designed to selectively target and inhibit a specific immune checkpoint receptor known as Tim-3 (T cell immunoglobulin and mucin domain-containing protein 3). Tim-3 is expressed on various immune cells, including T cells and dendritic cells, and plays a role in regulating immune responses.
By targeting Tim-3, rocatinlimab aims to block its inhibitory signals, thus potentially enhancing the anti-tumor immune response and promoting the immune system’s ability to attack cancer cells.
Spectrum:
rocatinlimab was being investigated for its potential use in treating various types of cancers, particularly solid tumors, and hematological malignancies. The rationale behind its development is to leverage the immune system’s capabilities to target and destroy cancer cells more effectively.
limited information available
Black Box Warning:
None
Pregnancy consideration:
No data is available for usage during pregnancy.
Breastfeeding warnings:
No data is available regarding the secretion of the drug in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: rocatinlimab
Why do we use rocatinlimab?
rocatinlimab’s current status in clinical development for the treatment of moderate-to-severe atopic dermatitis. While the Phase 2b trial results show promising efficacy and safety, Phase III clinical trials are essential to confirm and further evaluate these findings in a larger patient population. Phase III trials typically involve more participants and are crucial in providing additional evidence on the drug’s effectiveness and safety profile, which is necessary for regulatory approval.
The FDA and other regulatory agencies require comprehensive data from well-designed Phase III trials to assess a drug’s benefit-risk profile before considering approval. If rocatinlimab continues to demonstrate positive results in these larger-scale trials and proves to be safe and effective for the intended indication, it may have the potential to receive regulatory approval for treating moderate-to-severe atopic dermatitis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
